Physician profile
Patrick MD Bearden
NPI 1336791979
$5,010.88
in general payments reported to CMS, 2019-2025
33 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2022: $871 · 2023: $1,832 · 2024: $1,166 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,997 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.89 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.58 | 2022-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $709.51 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $353.26 | 2022-2025 | |
| Amgen INC. | $287.57 | 2022-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $258.44 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $244.94 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $214.89 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $211.37 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Shionogi INC | $211.09 | 2022-2025 | Fetroja |
| Bayer Healthcare Pharmaceuticals INC. | $189.98 | 2022-2025 | |
| Abbott Laboratories | $189.11 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $183.42 | 2022-2024 | Dexcom G6 Transmitter |
| Melinta Therapeutics, LLC | $158.99 | 2022-2024 | Kimyrsa, Vabomere, Rezzayo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.47 | 2023-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $110.52 | 2022-2025 | Trelegy Ellipta, Arexvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $70.57 | 2022-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company Ltd. | $66.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $53.74 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $51.68 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $47.89 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Halozyme INC | $44.61 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $41.86 | 2023-2025 | Rexulti |
| Insmed, INC. | $40.53 | 2025 | Brinsupri, Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.83 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $36.51 | 2022 | |
| Ardelyx, INC. | $33.29 | 2024-2025 | Ibsrela |
| Esperion Therapeutics, INC. | $31.33 | 2023 | Nexletol |
| Astellas Pharma US INC | $20.18 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $19.71 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $19.45 | 2023 | Cologuard Collection Kit |
| Csl Behring | $19.17 | 2024 | Hizentra |
| Inspire Medical Systems, INC. | $19.05 | 2025 | Inspire |
| Viiv Healthcare Company | $13.98 | 2024 | Rukobia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bearden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.